此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

一项多中心、开放标签 I 期临床研究,旨在评估 BL-M11D1 在复发/难治性急性髓系白血病患者中的安全性、耐受性、药代动力学特征和初步疗效

2026年9月21日 更新者:SystImmune Inc.

一项多中心、开放标签 I 期临床研究,旨在评估 BL-M11D1 在复发/难治性急性髓系白血病患者中的安全性、耐受性、药代动力学特征和初步疗效。

The objective of this study to evaluate the safety, tolerability, pharmacokinetic profile, and preliminary efficacy of BL-M11D1 in patients with relapsed/refractory acute myeloid leukemia.

研究概览

详细说明

BL-M11D1-HM-101 is a multi-center, Phase 1 study to evaluate the safety, tolerability, pharmacokinetic profile, and preliminary efficacy of BL-M11D1 in patients with relapsed/refractory acute myeloid leukemia.

This study will be conducted in two parts (dose escalation, and dose finding). Cohort A will be dosed on Days 1, 8,15 of a continuous 28-day treatment cycle. The cohort has different dose groups. Cohort B will be dosed on Days 1, 4, 7 or 8 of a continuous 28-day treatment cycle. The cohorts have different dose groups.

研究类型

介入性

注册 (实际的)

52

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • California
      • Duarte、California、美国、91010
        • City of Hope
      • Los Angeles、California、美国、90095
        • UCLA Ronald Reagan Medical Center
    • Colorado
      • Aurora、Colorado、美国、80045
        • University of Colorado Anschutz Medical Campus
    • Connecticut
      • New Haven、Connecticut、美国、06511
        • Yale Cancer Center, Smilow Cancer Hospital at Yale New Haven
    • Florida
      • Tampa、Florida、美国、33612
        • Moffitt Cancer Center
    • Illinois
      • Chicago、Illinois、美国、60611
        • Northwestern Memorial Hospital
    • Maryland
      • Baltimore、Maryland、美国、21287
        • The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    • Michigan
      • Grand Rapids、Michigan、美国、49546
        • START Midwest/The Cancer and Hematology Center
    • New Jersey
      • Hackensack、New Jersey、美国、07601
        • John Theurer Cancer Center-Hackensack
    • Ohio
      • Cincinnati、Ohio、美国、45236
        • Oncology Hematology Care Clinical Trials, LLC
      • Columbus、Ohio、美国、43210
        • The Ohio State University Comprehensive Cancer Center
    • Oregon
      • Eugene、Oregon、美国、24224
        • WVCI Oncology Associates of Oregon
      • Portland、Oregon、美国、97239
        • Oregon Health and Science University
    • Pennsylvania
      • Philadelphia、Pennsylvania、美国、19111
        • Temple Health Fox Chase Cancer Center
    • Tennessee
      • Nashville、Tennessee、美国、37203
        • SCRI -TriStar BMT
    • Texas
      • Houston、Texas、美国、77030
        • MD Anderson Cancer Center
    • Virginia
      • Fairfax、Virginia、美国、22031
        • Virginia Cancer Specialists
    • Washington
      • Seattle、Washington、美国、98109
        • Fred Hutchinson Cancer Center

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Signed the informed consent
  2. Age ≥18 years
  3. Has a life expectancy of ≥3 months
  4. Relapsed and/or refractory CD33-positive AML as determined by local pathology review that has failed initial standard of care therapy. Diagnosis of primary AML or AML secondary to myelodysplastic syndromes. Relapsed or refractory status. CD33-positive as confirmed by local flow cytometry or cytology
  5. Has an Eastern Cooperative Oncology Group performance status (ECOG PS) 0 to 2
  6. Toxicity of previous anticancer therapy has returned to Grade ≤1 as defined by NCI CTCAE V5.0, except for alopecia and endocrinopathies controlled by replacement therapy that must be Grade ≤2
  7. Has adequate liver and renal function before registration, defined as: a. Hepatic function: Total bilirubin (TBIL) ≤1.5×ULN (≤3×ULN for subjects with Gilbert's syndrome), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5×ULN b. Renal function: Creatinine clearance ≥50 mL/min (Cockcroft-Gault, Chronic Kidney Disease Epidemiology Collaboration [CKD-Epi], or Modification of Diet in Renal Disease Study [MDRD] equations)
  8. Sexually active fertile subjects and their partners must agree to use highly effective methods of contraception during the course of the study and for 7 months after the last dose of study treatment. An additional contraceptive method, such as a barrier method (eg, condom), is recommended
  9. Women of childbearing potential (WOCBP) must have a negative serum pregnancy test at screening and must be nonlactating

Exclusion Criteria:

  1. Subjects with acute promyelocytic leukemia (APL) or chronic myelogenous leukemia in blast crisis (CML)

  2. Chemotherapy, biological therapy, immunotherapy, radical radiotherapy, major surgery, targeted therapy (including small molecule inhibitor of tyrosine kinase), and other anticancer therapy within 2 weeks) prior to the first administration; mitomycin and nitrosoureas treatment within 6 weeks prior to the first administration, or palliative radiotherapy within 2 weeks prior to the first administration

  3. Subjects with history of severe heart disease, such as symptomatic congestive heart failure (CHF) ≥ Grade 2 (CTCAE 5.0), New York Heart Association (NYHA) ≥ Grade 2 heart failure, history of transmural myocardial infarction, unstable cardiac arrhythmias or angina pectoris within 6 months before screening

  4. Subjects with prolonged QT interval (QTcF >470 msec), complete left bundle branch block, Grade 3 atrioventricular block or a history of additional risk factors for Torsades de Pointes (TdP; eg, heart failure as defined in Exclusion Criterion 3, chronic or recurrent hypokalemia that requires medical intervention, congenital long QT syndrome, family history of long QT syndrome) or any current concomitant medication known to prolong the QT/QTc interval or cause TdP

  5. Active autoimmune diseases and inflammatory diseases, such as: systemic lupus erythematosus, psoriasis requiring systemic treatment, rheumatoid arthritis, inflammatory bowel disease and Hashimoto's thyroiditis, etc., except for Type I diabetes, hypothyroidism that can be controlled only by standard of care treatment, and skin diseases that do not require systemic treatment (such as vitiligo, psoriasis)

  6. Subjects with other prior or concurrent malignancies except for basal cell carcinoma of the skin, squamous cell carcinoma of the skin and/or carcinoma in situ after adequate resection, or other malignancy treated with curative intent with as disease-free interval of at least 1 year

  7. Subjects with poorly controlled hypertension or uncontrolled hypertension by two or more antihypertensive drugs (systolic blood pressure >150 mmHg or diastolic blood pressure >100 mmHg)

  8. Subjects with active acute or chronic graft vs. host disease (aGVHD or cGVHD) should be excluded from this study. Subjects with GVHD who are receiving treatment with systemic glucocorticoids >10 mg/day equivalent of prednisone should also be excluded from the study; however, treatment with low-dose glucocorticoids (≤10 mg/day equivalent of prednisone) is permitted

  9. Subjects currently receiving immunosuppressive therapy should be excluded from this study.

  10. Clinical evidence of disseminated intravascular coagulation (DIC). Smoldering low grade DIC is allowed after discussion with the sponsor

  11. Subjects with stroke or transient ischemic attack (TIA) within 6 months before screening

  12. Subjects with a thromboembolic event (eg, deep vein thrombosis [DVT] or pulmonary embolism [PE]) within 6 months before screening except for those who are clinically stable and receiving treatment with adequate anticoagulant therapy for at least 3 weeks before screening

  13. Subjects with active central nervous system (CNS) AML will be excluded. A lumbar puncture does not need to be performed unless there is clinical suspicion of CNS involvement per investigator judgment. Concurrent therapy for CNS prophylaxis or continuation of therapy for controlled CNS AML is allowed with the approval of the sponsor

  14. Subjects with pre-existing ≥Grade 2 peripheral neuropathy

  15. Subjects with advanced/ clinically significant lung diseases, such as poorly controlled COPD and asthma, restrictive lung disease, pulmonary hypertension etc.

  16. Subjects who have a history of noninfectious interstitial lung disease (ILD)/ pneumonitis that required treatment with steroids, have current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening

  17. Subjects who have a history of anaphylaxis or severe hypersensitivity to recombinant humanized antibodies or human-mouse chimeric antibodies or any of the components of BL-M11D1

  18. Subjects with known human immunodeficiency virus infection (HIV Ab positive) Subjects are allowed to participate if all of the following criteria are met: (1) Undetectable HIV RNA and CD4 count ≥350 cells/μL at screening, (2) No AIDS defining opportunistic infection within 12 months prior to screening, (3) On stable antiretroviral therapy (ART) for at least 4 weeks prior to screening with projected continuation of ART as clinically indicated while on the study

  19. Subjects with active Hepatitis B virus (HBV) infection (positive HBsAg test). Subjects with chronic inactive HBV infection are eligible if they meet all of the following criteria:

    1. Have a HBV DNA viral load ≤ 500 IU/mL
    2. Have normal AST and ALT, OR if liver involvement is present, has AST and ALT <3 × ULN which are not attributed to HBV infection
    3. on antiviral treatment, as clinically indicated
  20. Subjects with active Hepatitis C virus (HCV) infection (HCV antibody positive and HCV-RNA > the lower limit of detection). Subjects with a positive anti-HCV antibody are eligible only if PCR is negative for HCV RNA

  21. Subjects with active or latent tuberculosis

  22. Subjects with active and uncontrolled infections requiring IV antibiotic, antiviral, or antifungal treatment, such as severe pneumonia, bacteremia, sepsis, etc., within 1 week prior to first dose of study treatment. Subjects on stable oral antimicrobials with no clinical or laboratory evidence of active infection are eligible

  23. Received an investigational drug within 2 weeks prior to first dose of study treatment.

  24. Subjects who are pregnant, breastfeeding, or planning to become pregnant during the study

  25. Prior treatment with a topoisomerase inhibitor-based antibody-drug conjugate (ADC.)

  26. Previous history of significant gastrointestinal conditions, including Grade 3 or higher diarrhea, colitis, gastrointestinal bleeding and history of major gastrointestinal surgeries

28. Progressed on more than 2 different lines of systemic cytotoxic therapies; patients with 3 prior lines of systemic cytotoxic therapy or with prior allogeneic stem cell transplant may be enrolled upon consultation and approval from the sponsor

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:非随机化
  • 介入模型:顺序分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Experimental: Cohort A BL-M11D1 administered Days 1, 8 and 15 in 28-day cycle

Cohort A: BL-M11D1 will be administered on Days 1, 8 and 15 by intravenous infusion every 28 days.

The study includes 2 parts:

Part 1 Dose escalation and Dose Finding

实验性的:Experimental: Cohort B BL-M11D1 administered Days 1, 4 7 or 8 in 28-day cycle

Cohort B: BL-M11D1 will be administered on Days 1,4, 7 or 8 by intravenous infusion every 28 days.

The study includes 2 parts:

Part 1 Dose escalation and Dose Finding

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Participants with dose-limiting toxicities
大体时间:1 Year

DLTs are defined as any of the following events that are not clearly due to the underlying disease, disease progression, or extraneous causes:

  • Any treatment-emergent adverse event (TEAE) of ≥ Grade 3 except those due to disease progression or extraneous cause
  • Any TEAE that leads to dose reduction or withdrawal Nonhematologic toxicities
  • Death
  • Hy's law cases
  • Grade ≥3 nonhematologic toxicities (with exceptions) Hematologic toxicity
  • Grade 4 thrombocytopenia or neutropenia lasting >42 days in the absence of persistent leukemia
  • Grade ≥3 platelet count decreased with clinically significant hemorrhage
1 Year
Participants with Serious Adverse Events (SAEs) and treatment-emergent adverse events (TEAEs)
大体时间:1 Year

Measuring the number of patients with serious adverse events (SAEs) and treatment-emergent adverse events (TEAEs)

1 Year
To determine the minimum safe and effective dose (MSED), maximum tolerated dose (MTD) if reached, and maximum administered dose (MAD) of BL-M11D1 in AML
大体时间:1 Year

Determine the highest BL-M11D1 dose level at which ≤33% subjects experience a DLT during the DLT evaluation period and highest BL-M11D1 dose administered in the event and MTD cannot be defined.

1 Year

次要结果测量

结果测量
措施说明
大体时间
Cmax of BL-M11D1
大体时间:1 Year

Calculate maximum (peak) observed concentration of BL-M11D1

1 Year
Tmax of BL-M11D1
大体时间:1 Year

Calculate time of maximum observed concentration of BL-M1D1

1 Year
Tmax of free payload ED-04
大体时间:1 Year

Calculate time of maximum observed concentration of free payload ED-04

1 Year
Cmax of free payload ED-04
大体时间:1 Year

Calculate maximum (peak) observed concentration of free payload ED-04

1 Year
AUC(0-8) of BL-M11D1
大体时间:1 Year

Calculate area under the serum concentration-time curve of BL-M11D1 from time 0 to 8 hours

1 Year
AUC(0-8) of free payload ED-04
大体时间:1 Year

Calculate area under the serum concentration-time curve of free payload ED-04 from time 0 to 8 hours

1 Year
AUC(last) of BL-BM11D1
大体时间:1 Year

Calculate area under the serum concentration-time curve up of BL-M11D1 to the last quantifiable time

1 Year
AUC(last) of free payload ED-04
大体时间:1 Year

Calculate area under the serum concentration-time curve up of free payload ED-04 to the last quantifiable time

1 Year
Tmax of anti-CD33 antibody
大体时间:1 Year

Calculate time of maximum observed concentration of anti-CD33 antibody

1 Year
AUC (0-8) of anti-CD33 antibodies
大体时间:1 Year

Calculate area under the serum concentration-time curve of anti-CD33 antibodies from time 0 to 8 hours

1 Year
AUC (last) anti-CD33 antibodies
大体时间:1 Year

Calculate area under the serum concentration-time curve up of anti-CD33 antibodies to the last quantifiable time

1 Year
Overall Response Rate (ORR)
大体时间:1 Year

To assess the clinical efficacy of BL-M11D1 as measured by ORR using RECIST criteria v 1.1

1 Year
Duration of response (DOR)
大体时间:1 Year

To access the clinical efficacy of BL-M11D1 as measured by DOR using RECIST criteria 1.1

1 Year
Complete Remission (CR)
大体时间:1 Year

To assess the anti-cancer activity of BL-M11D1 as measured by CR using the European LeukemiaNet (ELN) 2022 AML criteria.

1 Year
CR with partial hematologic recovery (CRh)
大体时间:1 Year

To assess the anti-cancer activity of BL-M11D1 as measured by CR using the European LeukemiaNet (ELN) 2022 AML criteria.

1 Year
CR with incomplete hematologic recovery (CRi)
大体时间:1 Year

To assess the anti-cancer activity of BL-M11D1 as measured by CR using the European LeukemiaNet (ELN) 2022 AML criteria.

1 Year
CR/CRi, CRs with or without measurable residual disease (MRD)
大体时间:1 Year

To assess the anti-cancer activity of BL-M11D1 as measured by CR using the European LeukemiaNet (ELN) 2022 AML criteria.

1 Year
morphologic leukemia-free state (MLFS)
大体时间:1 Year

To assess the anti-cancer activity of BL-M11D1 as measured by CR using the European LeukemiaNet (ELN) 2022 AML criteria.

1 Year
partial remission (PR)
大体时间:1 Year

To assess the anti-cancer activity of BL-M11D1 as measured by CR using the European LeukemiaNet (ELN) 2022 AML criteria.

1 Year

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Olu Lawson、SystImmune Inc.

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2024年12月19日

初级完成 (实际的)

2026年9月16日

研究完成 (实际的)

2026年9月16日

研究注册日期

首次提交

2024年11月27日

首先提交符合 QC 标准的

2024年11月27日

首次发布 (实际的)

2024年12月3日

研究记录更新

最后更新发布 (实际的)

2026年9月24日

上次提交的符合 QC 标准的更新

2026年9月21日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅